Advanced Filters
noise

Biejing, China Clinical Trials

A listing of Biejing, China clinical trials actively recruiting patients volunteers.

Found 2,326 clinical trials

MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.

18 - 75 years of age All Phase 1
C Chunmei Bai, M.D.

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are prognostic value of baseline MRD; the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood …

18 years of age All Phase N/A
Y Yang Liu, M.D

CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive Relapsed/Refractory Lymphoma . In this clinical trial, at least 12 eligible patients in dose escalation period will …

18 - 75 years of age All Phase 1/2

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of subretinal administration of FT-001 in subjects with biallelic RPE65 mutation-associated retinal dystrophy.

8 - 45 years of age All Phase 1/2
N Ningning Lu, Doctor

MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer

To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer To assess the acute and late toxicities, efficacy and quality of life for patients treated by MRL-SBRT To simulate the dose planning and assess the feasibility of simultaneous-boost for MR-prominent foci To investigate the …

18 years of age Male Phase N/A
H Hao Jing, M.D.

Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.

35 years of age Female Phase 2
Y Yu Wang, Dr.

Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD

This trial is a randomized (1:1) phase III open label study of frontline mini-MTX plus methylprednisolone 2mg/kg/day compared to methylprednisolone 2mg/kg in allogeneic stem cell transplant recipients with grade 2-4 aGVHD.

15 - 65 years of age All Phase 3
C Caixia Li, M.D.

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.

18 years of age All Phase 1/2
X Xinyu Sun

A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis

The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).

40 years of age All Phase 3
A Aiping Zhou, MD

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

This is a prospective, multicenter, exploratory study. Patients with advanced esophageal or gastro-esophageal junction squamous carcinoma who had progressed on first-line chemotherapy combined with immune checkpoint inhibitors were treated with CDK4/6 inhibitor Palbociclib combined with Afatinib. Dose titration was used to determine the final dose, and objective antitumor efficacy was …

18 - 75 years of age All Phase 2

Simplify language using AI